A Koyanagi1,2, A Stickley3, J M Haro1,2. 1. Parc Sanitari Sant Joan de Déu, Universitat de Barcelona, Fundació Sant Joan de Déu, Barcelona, Spain. 2. Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Madrid, Spain. 3. The Stockholm Centre for Health and Social Change (SCOHOST), Södertörn University, Huddinge, Sweden.
Abstract
OBJECTIVE: To assess the association between psychotic symptoms and smoking among community-dwelling adults in 44 countries. METHOD: Data from the World Health Survey (WHS) for 192 474 adults aged ≥18 years collected in 2002-2004 were analyzed. The Composite International Diagnostic Interview was used to identify four types of past 12-month psychotic symptoms. Smoking referred to current daily and non-daily smoking. Heavy smoking was defined as smoking ≥30 tobacco products/day. RESULTS: The pooled age-sex-adjusted OR (95% CI) of psychotic symptoms (i.e., at least one psychotic symptom) for smoking was 1.35 (1.27-1.43). After adjustment for potential confounders, compared to those with no psychotic symptoms, the ORs (95% CIs) for smoking for 1, 2, and ≥3 psychotic symptoms were 1.20 (1.08-1.32), 1.25 (1.08-1.45), and 1.36 (1.13-1.64) respectively. Among daily smokers, psychotic symptoms were associated with heavy smoking (OR = 1.45, 95% CI = 1.10-1.92), and individuals who initiated daily smoking at ≤15 years of age were 1.22 (95% CI = 1.05-1.42) times more likely to have psychotic symptoms. CONCLUSIONS: An increased awareness that psychotic symptoms are associated with smoking is important from a public health and clinical point of view. Future studies that investigate the underlying link between psychotic symptoms and smoking prospectively are warranted.
OBJECTIVE: To assess the association between psychotic symptoms and smoking among community-dwelling adults in 44 countries. METHOD: Data from the World Health Survey (WHS) for 192 474 adults aged ≥18 years collected in 2002-2004 were analyzed. The Composite International Diagnostic Interview was used to identify four types of past 12-month psychotic symptoms. Smoking referred to current daily and non-daily smoking. Heavy smoking was defined as smoking ≥30 tobacco products/day. RESULTS: The pooled age-sex-adjusted OR (95% CI) of psychotic symptoms (i.e., at least one psychotic symptom) for smoking was 1.35 (1.27-1.43). After adjustment for potential confounders, compared to those with no psychotic symptoms, the ORs (95% CIs) for smoking for 1, 2, and ≥3 psychotic symptoms were 1.20 (1.08-1.32), 1.25 (1.08-1.45), and 1.36 (1.13-1.64) respectively. Among daily smokers, psychotic symptoms were associated with heavy smoking (OR = 1.45, 95% CI = 1.10-1.92), and individuals who initiated daily smoking at ≤15 years of age were 1.22 (95% CI = 1.05-1.42) times more likely to have psychotic symptoms. CONCLUSIONS: An increased awareness that psychotic symptoms are associated with smoking is important from a public health and clinical point of view. Future studies that investigate the underlying link between psychotic symptoms and smoking prospectively are warranted.
Authors: Jordan E DeVylder; Ian Kelleher; Monique Lalane; Hans Oh; Bruce G Link; Ai Koyanagi Journal: JAMA Psychiatry Date: 2018-07-01 Impact factor: 21.596
Authors: Louisa Degenhardt; Sukanta Saha; Carmen C W Lim; Sergio Aguilar-Gaxiola; Ali Al-Hamzawi; Jordi Alonso; Laura H Andrade; Evelyn J Bromet; Ronny Bruffaerts; José Miguel Caldas-de-Almeida; Giovanni de Girolamo; Silvia Florescu; Oye Gureje; Josep M Haro; Elie G Karam; Georges Karam; Viviane Kovess-Masfety; Sing Lee; Jean-Pierre Lepine; Victor Makanjuola; Maria E Medina-Mora; Zeina Mneimneh; Fernando Navarro-Mateu; Marina Piazza; José Posada-Villa; Nancy A Sampson; Kate M Scott; Juan Carlos Stagnaro; Margreet Ten Have; Kenneth S Kendler; Ronald C Kessler; John J McGrath Journal: Addiction Date: 2018-02-21 Impact factor: 6.526
Authors: Brendon Stubbs; Ai Koyanagi; Felipe Schuch; Joseph Firth; Simon Rosenbaum; Fiona Gaughran; James Mugisha; Davy Vancampfort Journal: Schizophr Bull Date: 2017-05-01 Impact factor: 9.306
Authors: Kate M Scott; Sukanta Saha; Carmen C W Lim; Sergio Aguilar-Gaxiola; Ali Al-Hamzawi; Jordi Alonso; Corina Benjet; Evelyn J Bromet; Ronny Bruffaerts; José Miguel Caldas-de-Almeida; Giovanni de Girolamo; Peter de Jonge; Louisa Degenhardt; Silvia Florescu; Oye Gureje; Josep M Haro; Chiyi Hu; Elie G Karam; Viviane Kovess-Masfety; Sing Lee; Jean-Pierre Lepine; Zeina Mneimneh; Fernando Navarro-Mateu; Marina Piazza; José Posada-Villa; Nancy A Sampson; Juan Carlos Stagnaro; Ronald C Kessler; John J McGrath Journal: Psychol Med Date: 2018-02-26 Impact factor: 7.723
Authors: Brendon Stubbs; Ai Koyanagi; Nicola Veronese; Davy Vancampfort; Marco Solmi; Fiona Gaughran; André F Carvalho; John Lally; Alex J Mitchell; James Mugisha; Christoph U Correll Journal: BMC Med Date: 2016-11-22 Impact factor: 8.775
Authors: Brendon Stubbs; Nicola Veronese; Davy Vancampfort; Trevor Thompson; Cristiano Kohler; Patricia Schofield; Marco Solmi; James Mugisha; Kai G Kahl; Toby Pillinger; Andre F Carvalho; Ai Koyanagi Journal: Sci Rep Date: 2017-08-02 Impact factor: 4.379